Abstract: The present disclosure features useful oligonucleotide compositions and methods related thereto. The present disclosure encompasses the recognition that structural elements of oligonucleotides, such as base sequence, chemical modifications (e.g. modifications of sugar, base and/or internucleotide linkages) or patterns thereof, can have a significant impact on oligonucleotide properties and activities. The present disclosure also provides methods to treat disorders for which deamination of an adenosine in an mRNA produces a therapeutic result, e.g., in a subject in need thereof.
| # | Name | Date |
|---|---|---|
| 1 | 202417075332-STATEMENT OF UNDERTAKING (FORM 3) [04-10-2024(online)].pdf | 2024-10-04 |
| 2 | 202417075332-REQUEST FOR EXAMINATION (FORM-18) [04-10-2024(online)].pdf | 2024-10-04 |
| 3 | 202417075332-POWER OF AUTHORITY [04-10-2024(online)].pdf | 2024-10-04 |
| 4 | 202417075332-NOTIFICATION OF INT. APPLN. NO. & FILING DATE (PCT-RO-105-PCT Pamphlet) [04-10-2024(online)].pdf | 2024-10-04 |
| 5 | 202417075332-FORM 18 [04-10-2024(online)].pdf | 2024-10-04 |
| 6 | 202417075332-FORM 1 [04-10-2024(online)].pdf | 2024-10-04 |
| 7 | 202417075332-DRAWINGS [04-10-2024(online)].pdf | 2024-10-04 |
| 8 | 202417075332-DECLARATION OF INVENTORSHIP (FORM 5) [04-10-2024(online)].pdf | 2024-10-04 |
| 9 | 202417075332-COMPLETE SPECIFICATION [04-10-2024(online)].pdf | 2024-10-04 |
| 10 | 202417075332-Proof of Right [29-11-2024(online)].pdf | 2024-11-29 |
| 11 | 202417075332-FORM 3 [01-04-2025(online)].pdf | 2025-04-01 |